REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 15,309 Shares of Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 15,309 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $11.02, for a total value of $168,705.18. Following the transaction, the insider directly owned 232,617 shares in the company, valued at approximately $2,563,439.34. This represents a 6.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steve Pakola also recently made the following trade(s):

• On Tuesday, March 10th, Steve Pakola sold 5,124 shares of REGENXBIO stock. The stock was sold at an average price of $10.35, for a total value of $53,033.40.

REGENXBIO Stock Down 2.0%

NASDAQ RGNX opened at $10.04 on Thursday. REGENXBIO Inc. has a 52-week low of $7.35 and a 52-week high of $16.19. The business’s 50-day moving average price is $8.97 and its 200 day moving average price is $11.08. The firm has a market cap of $518.23 million, a P/E ratio of -2.67 and a beta of 1.12.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.38). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The company had revenue of $6.39 million for the quarter, compared to analysts’ expectations of $25.84 million. As a group, analysts anticipate that REGENXBIO Inc. will post -2.88 earnings per share for the current year.

Hedge Funds Weigh In On REGENXBIO

Hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue purchased a new position in REGENXBIO in the 3rd quarter valued at approximately $25,000. Aquatic Capital Management LLC purchased a new position in REGENXBIO in the 3rd quarter valued at approximately $37,000. Jones Financial Companies Lllp increased its stake in REGENXBIO by 44.4% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,270 shares in the last quarter. Captrust Financial Advisors purchased a new position in REGENXBIO in the 2nd quarter valued at approximately $85,000. Finally, Prudential Financial Inc. purchased a new position in REGENXBIO in the 2nd quarter valued at approximately $87,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on RGNX. The Goldman Sachs Group reduced their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Chardan Capital reduced their price objective on shares of REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. HC Wainwright reduced their price objective on shares of REGENXBIO from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Wall Street Zen downgraded shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Finally, Morgan Stanley reduced their price objective on shares of REGENXBIO from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and an average target price of $27.50.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.